This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

ASCP Corner

Real-Life Dosing With Second-Generation Antipsychotics

Christoph U. Correll, MD

Published: December 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

This is the first of 2 articles addressingmethodological issues regarding real-lifedosing and switching strategies whentreating patients with second-generationantipsychotics.

When faced with nonresponse to an adequateduration of antipsychotic treatmentat maximum recommended doses, clinicianshave 4 basic options to improvesymptomatic and/or functional response:(1) wait for the occurrence of a potentiallydelayed response; (2) augment with anothermedication (of the same or a differentclass); (3) switch to another medication(of the same or a different class); or(4) increase the dose beyond the upperdose range used in U.S. Food and DrugAdministration (FDA) approval trials. Ifsufficient data were available, a fifth optioncould be to check for the presence oftherapeutic antipsychotic drug levels.’ ‹

Volume: 66

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF